PT  - JOURNAL ARTICLE
AU  - Braña, Ignacio
AU  - Loredo, Marta
AU  - Pardo, Estefanía
AU  - Burger, Stefanie
AU  - Fernández-Bretón, Eva
AU  - Queiro, Rubén
TI  - Patients With Psoriatic Arthritis–Related Enthesitis and Persistence on Tofacitinib Under Real-World Conditions
AID  - 10.3899/jrheum.2024-0016
DP  - 2024 Jul 01
TA  - The Journal of Rheumatology
PG  - 682--686
VI  - 51
IP  - 7
4099  - http://www.jrheum.org/content/51/7/682.short
4100  - http://www.jrheum.org/content/51/7/682.full
SO  - J Rheumatol2024 Jul 01; 51
AB  - Objective Information on the persistence of tofacitinib (TOF) in psoriatic arthritis (PsA) is scarce in real-world conditions. Our objective was to analyze the persistence and safety of TOF under these conditions.Methods This was a single-center retrospective longitudinal observational study of all patients with PsA who received at least 1 dose of TOF. The main focus was on adverse events (AEs) and drug survival. Drug survival was analyzed by Kaplan-Meier curves and persistence explanatory factors by multivariate Cox regression models. The hazard ratio (HR) was used to measure association.Results Seventy-two patients were included, 54 women and 18 men, mean age 51.9 (SD 11.1) years, mean disease duration of 10.4 (SD 6.99) years. TOF was ≥ third line of therapy in > 70% of cases. The median survival was 13.0 (IQR 5.3-29.0) months. One-year retention rate was 52.7% (95% CI 42.4-65.6). TOF survival was not influenced by sex, disease duration, comorbidities, or line of treatment. Younger patients (HR 0.96, P = 0.01) and those with enthesitis (HR 0.37, P = 0.03) showed lower odds of drug discontinuation. The overall rate of AEs was 52.9 (95% CI 38.5-70.6)/100 person-years. Most AEs occurred during the first 6 months of exposure.Conclusion In this real-world study, TOF showed a reasonably good retention rate in a PsA population that was mostly refractory to biologic and oral targeted synthetic disease-modifying antirheumatic drugs. There were no new causes for concern regarding safety. Patients with refractory PsA and enthesitis might be a specific target population for this drug.